Meeting Coverage
AAD
American Academy of Dermatology
Latest AAD Meetings
Rapid reduction in itch, sleep disturbance, nodules after first dose of nemolizumab
Responses often maintained after drug withdrawal, long-term persistence with ongoing treatment
Rates of 90% clearance approaching 50% at 12 weeks, with 100% clearance rates as high as 33%
Disease status, itch improved significantly within 1 to 2 weeks with roflumilast cream
New analyses show "unprecedented" rates of 50% to 100% improvement
About 40% of patients go from nearly hairless to almost a full head of hair with deuruxolitinib
"Dramatic improvement" at 16 weeks with IL-23 blocker after lack of response to anti-IL-17 drug
AAD data also promising for therapies in psoriasis, pyoderma gangrenosum
No reduction in vascular inflammation with apremilast but significant reduction in body fat
Durable improvement in pigmentation with topical ruxolitinib, oral ritlecitinib
Rapid responses in a majority of patients in small trial of eblasakimab
Dupilumab reduces itch, lesion count in first phase III trial for prurigo nodularis
Oral baricitinib superior to placebo at 36 weeks in BRAVE-AA1 and BRAVE-AA2 trials
Plus: First-in-class drug shows promise in AD, BTK inhibitor active in pemphigus